Evercore Wealth Management Has Trimmed Oracle (ORCL) Stake By $497,025; Can-fite Biopharma Ltd Sponsored Adr (israel) (NYSEAMERICAN:CANF) SI Decreased By 15.21%

April 23, 2018 - By David King

Oracle Corporation (NYSE:ORCL) Logo

Evercore Wealth Management Llc decreased Oracle Corp (ORCL) stake by 6.98% reported in 2017Q4 SEC filing. Evercore Wealth Management Llc sold 10,575 shares as Oracle Corp (ORCL)’s stock declined 4.18%. The Evercore Wealth Management Llc holds 140,935 shares with $6.66M value, down from 151,510 last quarter. Oracle Corp now has $186.99B valuation. The stock decreased 0.92% or $0.42 during the last trading session, reaching $45.81. About 9.37 million shares traded. Oracle Corporation (NYSE:ORCL) has risen 1.20% since April 23, 2017 and is uptrending. It has underperformed by 10.35% the S&P500.

Can-fite Biopharma Ltd Sponsored Adr (israel) (NYSEAMERICAN:CANF) had a decrease of 15.21% in short interest. CANF’s SI was 129,900 shares in April as released by FINRA. Its down 15.21% from 153,200 shares previously. With 65,400 avg volume, 2 days are for Can-fite Biopharma Ltd Sponsored Adr (israel) (NYSEAMERICAN:CANF)’s short sellers to cover CANF’s short positions. The SI to Can-fite Biopharma Ltd Sponsored Adr (israel)’s float is 0.81%. The stock decreased 0.73% or $0.01 during the last trading session, reaching $1.37. About 11,864 shares traded. Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) has declined 23.94% since April 23, 2017 and is downtrending. It has underperformed by 35.49% the S&P500.

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company has market cap of $28.08 million. The company's lead drug candidate is CF101, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It currently has negative earnings. It also develops CF102 that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction.

Among 42 analysts covering Oracle (NYSE:ORCL), 27 have Buy rating, 0 Sell and 15 Hold. Therefore 64% are positive. Oracle had 115 analyst reports since July 30, 2015 according to SRatingsIntel. Jefferies maintained the shares of ORCL in report on Friday, September 15 with “Buy” rating. The stock of Oracle Corporation (NYSE:ORCL) has “Hold” rating given on Thursday, June 22 by Oppenheimer. The firm has “Market Perform” rating by BMO Capital Markets given on Wednesday, March 16. The firm earned “Neutral” rating on Tuesday, March 20 by Bank of America. The firm has “Buy” rating given on Friday, September 23 by Stifel Nicolaus. SunTrust upgraded the stock to “Buy” rating in Wednesday, September 16 report. The stock of Oracle Corporation (NYSE:ORCL) earned “Outperform” rating by BMO Capital Markets on Thursday, June 22. The stock of Oracle Corporation (NYSE:ORCL) earned “Buy” rating by Stifel Nicolaus on Thursday, September 17. The firm has “Neutral” rating given on Tuesday, July 19 by Atlantic Securities. The stock of Oracle Corporation (NYSE:ORCL) has “Buy” rating given on Thursday, September 17 by Nomura.

Investors sentiment increased to 1.15 in Q4 2017. Its up 0.02, from 1.13 in 2017Q3. It improved, as 80 investors sold ORCL shares while 488 reduced holdings. 126 funds opened positions while 526 raised stakes. 2.29 billion shares or 1.37% less from 2.32 billion shares in 2017Q3 were reported. Retirement Of Alabama owns 3.04M shares. Sandler Capital Mngmt invested in 0.15% or 22,200 shares. Curbstone Fincl Mgmt Corp has invested 0.16% in Oracle Corporation (NYSE:ORCL). New Hampshire-based Wendell David Assoc has invested 0.04% in Oracle Corporation (NYSE:ORCL). Foyston Gordon Payne Inc invested in 4.51% or 501,831 shares. Sageworth has 0% invested in Oracle Corporation (NYSE:ORCL) for 83 shares. Edgemoor Inc holds 11,187 shares. Cap Advsrs Limited Liability stated it has 4,550 shares or 0.07% of all its holdings. Invesco Limited has invested 0.35% in Oracle Corporation (NYSE:ORCL). Sentry Investments has 2.64% invested in Oracle Corporation (NYSE:ORCL). Cullen Cap Ltd has 20,200 shares. Pennsylvania-based Cs Mckee Limited Partnership has invested 1.46% in Oracle Corporation (NYSE:ORCL). Picton Mahoney Asset Mngmt accumulated 112,400 shares or 0.14% of the stock. Barton Investment accumulated 11,375 shares. Centurylink Invest Mngmt holds 0.33% or 19,529 shares.

Analysts await Oracle Corporation (NYSE:ORCL) to report earnings on June, 20. They expect $0.86 EPS, up 4.88% or $0.04 from last year’s $0.82 per share. ORCL’s profit will be $3.51B for 13.32 P/E if the $0.86 EPS becomes a reality. After $0.75 actual EPS reported by Oracle Corporation for the previous quarter, Wall Street now forecasts 14.67% EPS growth.

Oracle Corporation (NYSE:ORCL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: